Integrative computational approach identifies new targets in CD4+ T cell-mediated immune disorders
CD4+ T cells provide adaptive immunity against pathogens and abnormal cells, and they are also associated with various immune related diseases. CD4+ T cells metabolism is dysregulated in these pathologies and represents an opportunity for drug discovery and development. Genome-scale metabolic modeling offers an opportunity to accelerate drug discovery by providing high-quality information about possible target space in the context of a modeled disease. Here, we develop genome-scale models of naive, Th1, Th2 and Th17 CD4+ T cell subtypes to map metabolic perturbations in rheumatoid arthritis, multiple sclerosis, and primary biliary cholangitis. We subjected these models to in silico simulations for drug response analysis of existing FDA-approved drugs, and compounds. Integration of disease-specific differentially expressed genes with altered reactions in response to metabolic perturbations identified 68 drug targets for the three autoimmune diseases. In vitro experimental validations together with literature-based evidence showed that modulation of fifty percent of identified drug targets has been observed to lead to suppression of CD4+ T cells, further increasing their potential impact as therapeutic interventions. The used approach can be generalized in the context of other diseases, and novel metabolic models can be further used to dissect CD4+ T cell metabolism.